Rexahn shares soar ahead of update; Nycomed says Daxas setback won't stop IPO;

 @FierceBiotech: Sanofi opens R&D center in China. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion IPO on Friday prices at $5, closes at 5.02. High risk, no revenue not what investors are looking for these days. | Follow @JohnCFierce

> Shares of Rexahn vaulted 27 percent this morning as the company announced a corporate update for tomorrow. Report

> Despite a recent setback for its drug Daxas, which earned a thumb's down vote recently from an FDA advisory panel, Nycomed says it still plans to go public. Story

> The UK's Proximagen says it will gain an upfront payment as part of a new U.S. licensing deal for its epilepsy drug tonabersat. Story

> RXi and miRagen have inked a deal to collaborate on new drugs for heart and muscle diseases. No financial terms were revealed. Story

> GenVec says it presented "encouraging" clinical and preclinical malaria vaccine data at the Keystone Symposium--Malaria: New Approaches to Understanding Host-Parasite Interactions. GenVec release

> Optimer Pharmaceuticals released top-line results from its second fidaxomicin Phase III clinical study in patients with Clostridium difficile infection at the 20th Annual European Congress of Clinical Microbiology and Infectious Diseases. Optimer release

> Federal Bankruptcy Court Judge Theodor C. Albert has confirmed Cobalis Corp's plan for reorganization. Release

And Finally... Overlooking the obvious in your surroundings? That's because your brain predicts what you will see in familiar settings. It's only when you see something unusual that your brain kicks in. Report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.